• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.14
  • VXN 24.38
  • VXO 19.94
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





YES
Refresh      
ENDP (Endo International plc)
Last Trade 12.69 Dividend/Share 0 PE Ratio 4.36
Date November 16-2018 Dividend Yield 0.000 Return on Assets -9.89
Change -0.04 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -9.12 Price/Sale 0.975
Ask null LatestEPS Date 2017-12-31 Price to Book null
Volume null EPS ttm 2.91 Institutional % 162.8
Avg Volume 5.12M Shares Outstanding 224.34M Insider % null
Open 12.59 Float 224.34M Short Ratio null
Prev Close 12.73 Return On Equity -406.21 5 Year Change % -0.803
High 12.83 Consensus EPS 0.59 2 Year Change % -0.257
Low 12.33 No. of Estimate 8.000 1 Year Change % 0.683
52 Week High 18.5 EPS Surprise $ null YTD Change % 0.567
52 Week Low 5.27 EPS Surprise Percent 20.339 6 Month Change % 1.047
52 Week Change 73.836 EBITDA 0M 3 Month Change % -0.189
50 Day MA 16.2938 Revenue 0M 1 Month Change % -0.256
200 Day MA Gross Profit 0M 5 Day Change % -0.037
Market Cap 2846.94M Cash 0M 30 Day Change % -0.257
Beta 0.406264 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Company Profile

Endo Pharmaceuticals Holdings Inc., through its subsidiary, Endo Pharmaceuticals Inc., engages in the research, development, manufacture, marketing, and sale of branded and generic prescription pharmaceuticals in the United States. Its primary products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana and Opana ER, and Percocet for the relief of moderate to severe pain; Voltaren Gel for use in treating pain associated with osteoarthritis; Frova for the acute treatment of migraine headaches in adults; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas for the palliative treatment of advanced prostate cancer; Valstar, a sterile solution for intravesical instillation of valrubicin and BCG-refractory CIS of the bladder; Hydron Implant, a reservoir-based drug delivery system available for parenteral administration; Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; and Sanctura XR to treat OAB symptoms. The company also offers generic products, including Endocet and morphine sulfate. In addition, it provides various development stage products, which primarily comprise Aveed for the treatment of male hypogonadism; Fortesta for testosterone replacement therapy in male hypogonadism; Octreotide implant for the treatment of acromegaly; Urocidin for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing; and Axomadol in Phase II development for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company has a strategic alliance agreement with Penwest Pharmaceuticals Co. Endo Pharmaceuticals Holdings was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.